Article Text

Download PDFPDF
16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy for age-related macular degeneration: 12 month outcomes of a ‘radiation-first’ strategy
  1. Andrew A Moshfeghi1,
  2. Virgilio Morales-Canton2,
  3. Hugo Quiroz-Mercado2,3,
  4. Raul Velez-Montoya2,3,
  5. Alicia Zavala-Ayala2,
  6. Eugene Mark Shusterman4,
  7. Peter K Kaiser5,
  8. Steven R Sanislo6,
  9. Michael Gertner4,
  10. Darius M Moshfeghi6
  1. 1Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Palm Beach Gardens, Florida, USA
  2. 2Department of Retina, Associacion Para Evitar La Ceguera En Mexico, I.A.P., Mexico City, Mexico
  3. 3Department of Ophthalmology, Denver Health Medical Center, University of Colorado, Denver, Colorado, USA
  4. 4Oraya Therapeutics, Inc., Newark, California, USA
  5. 5Cleveland Clinic Foundation, Cole Eye Institute, Cleveland, Ohio, USA
  6. 6Department of Ophthalmology, Byers Eye Institute at Stanford University, Horngren Family Vitreoretinal Center, Stanford University School of Medicine, Palo Alto, California, USA
  1. Correspondence to Dr Darius M Moshfeghi, Department of Ophthalmology, Byers Eye Institute at Stanford University, Horngren Family Vitreoretinal Center, Stanford University School of Medicine, 2452 Watson Court, Palo Alto, CA 94303 USA; dariusm{at}


Background and objective To describe ‘radiation-first’ combination treatment with a non-invasive, low-voltage x-ray irradiation system followed by as needed ranibizumab for neovascular age-related macular degeneration (AMD).

Study design and methods Phase I study of non-invasive, low-voltage 16 Gy x-ray irradiation delivered in three beams via the inferior pars plana in patients with active neovascular AMD. Ranibizumab was administered as needed per protocol. Patients were followed monthly for safety and efficacy over 12 months.

Results 13 patients were enrolled and completed 12 months follow-up. Safety was good with no serious ocular/non-ocular adverse events or radiation-related ocular complications. 11 patients lost <15 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, seven gained ≥0 ETDRS letters and 0 gained ≥15 ETDRS letters. Patients received a total of 31 subsequent ranibizumab injections (of possible 156) over the 12 months following x-ray irradiation. Mean time to first injection was 3.9 months. One patient received no ranibizumab injections, three patients received one injection, four patients received two injections, and five patients received three or more injections.

Conclusions After 12 months, non-invasive, low-voltage x-ray irradiation with as needed ranibizumab rescue therapy demonstrated good safety with a visual acuity stabilising effect and reduction in retinal thickness in patients with neovascular AMD.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.